MX2017005282A - Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). - Google Patents

Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).

Info

Publication number
MX2017005282A
MX2017005282A MX2017005282A MX2017005282A MX2017005282A MX 2017005282 A MX2017005282 A MX 2017005282A MX 2017005282 A MX2017005282 A MX 2017005282A MX 2017005282 A MX2017005282 A MX 2017005282A MX 2017005282 A MX2017005282 A MX 2017005282A
Authority
MX
Mexico
Prior art keywords
disorders
compounds
new compounds
cancer
nik
Prior art date
Application number
MX2017005282A
Other languages
English (en)
Other versions
MX371153B (es
Inventor
John Gary Montana
Calum Macleod
Janusz Jozef Kulagowski
George Hynd
Samuel Edward Mann
Patrizia Tisselli
Colin Price Stephen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017005282A publication Critical patent/MX2017005282A/es
Publication of MX371153B publication Critical patent/MX371153B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, y en particular a inhibidores de la cinasa inductora de NF-KB (NIK - también conocida como MAP3K14) útiles para tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos y trastornos autoinmunitarios; la invención también se refiere a composiciones farmacéuticas que comprenden tales compuestos, a procesos para preparar tales compuestos y composiciones, y al uso de tales compuestos o composiciones farmacéuticas para prevenir o tratar enfermedades tales como el cáncer, trastornos inflamatorios, trastornos metabólicos, incluidas la obesidad y la diabetes, y trastornos autoinmunitarios.
MX2017005282A 2014-10-23 2015-10-22 Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). MX371153B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190068 2014-10-23
PCT/EP2015/074437 WO2016062792A1 (en) 2014-10-23 2015-10-22 New compounds as nik inhibitors

Publications (2)

Publication Number Publication Date
MX2017005282A true MX2017005282A (es) 2017-08-15
MX371153B MX371153B (es) 2020-01-20

Family

ID=51868764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005282A MX371153B (es) 2014-10-23 2015-10-22 Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).

Country Status (13)

Country Link
US (1) US10005776B2 (es)
EP (1) EP3209662B1 (es)
JP (1) JP6676048B2 (es)
KR (1) KR102500071B1 (es)
CN (1) CN107074855B (es)
AU (1) AU2015334917B2 (es)
BR (1) BR112017008045A2 (es)
CA (1) CA2960336C (es)
EA (1) EA030908B1 (es)
ES (1) ES2718557T3 (es)
IL (1) IL251780B (es)
MX (1) MX371153B (es)
WO (1) WO2016062792A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
BR112017025995A2 (pt) 2015-06-04 2018-08-14 Ospedale San Raffaele S.R.L. inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
CA2988011C (en) 2015-06-04 2021-03-23 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
EP3656762A1 (en) 2018-11-26 2020-05-27 Instituto Biomar S.A. Compounds for the treatment of nf-kb-related diseases or disorders
BR112021023796A2 (pt) 2019-05-31 2022-02-08 Janssen Pharmaceutica Nv Inibidores de moléculas pequenas de quinase indutora de nf-capab

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756103A2 (en) * 2004-04-26 2007-02-28 Pfizer, Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) * 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
CA2728767A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CA2827161A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag 6,5-heterocyclic propargylic alcohol compounds and uses therefor
CN103608014A (zh) * 2011-03-24 2014-02-26 罗楹 激酶抑制剂在治疗和预防炎症疾病中的用途
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
CA2960567C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Thienopyrimidine derivatives as nik inhibitors
KR102499862B1 (ko) 2014-10-23 2023-02-13 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸 유도체
EP3209663B1 (en) 2014-10-23 2018-12-12 Janssen Pharmaceutica N.V. New pyrazolopyrimidine derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors

Also Published As

Publication number Publication date
KR20170066473A (ko) 2017-06-14
CN107074855A (zh) 2017-08-18
EP3209662A1 (en) 2017-08-30
ES2718557T3 (es) 2019-07-02
JP6676048B2 (ja) 2020-04-08
AU2015334917A1 (en) 2017-03-23
WO2016062792A1 (en) 2016-04-28
KR102500071B1 (ko) 2023-02-14
EA030908B1 (ru) 2018-10-31
MX371153B (es) 2020-01-20
AU2015334917B2 (en) 2019-08-29
US10005776B2 (en) 2018-06-26
EP3209662B1 (en) 2019-01-09
IL251780A0 (en) 2017-06-29
CA2960336A1 (en) 2016-04-28
EA201790688A1 (ru) 2017-08-31
US20170334906A1 (en) 2017-11-23
CA2960336C (en) 2023-03-07
JP2017531681A (ja) 2017-10-26
BR112017008045A2 (pt) 2017-12-19
CN107074855B (zh) 2019-11-05
IL251780B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX371153B (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
MX2017005285A (es) Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
PH12017501921A1 (en) Novel compounds
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2016003863A (es) Nuevos derivados de 3-(1h-pirazol-4-il)-1h-pirrolo[2,3-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX2016003861A (es) Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX369159B (es) Derivados de 3-(2-aminopiridin-4-il)-5-(3-hidroxipropinil)-1h-pirr olo[2,3-c]piridina como inhibidores de la nik para el tratamiento del cancer.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Legal Events

Date Code Title Description
FG Grant or registration